Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P I Thompson

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Chemotherapy and Pharmacology|October 6, 2006
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trialM B Jameson, B C Baguley, P Kestell, et al.
Cancer Chemotherapy and Pharmacology|June 15, 1999
Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamideM R McCrystal, B D Evans, V J Harvey, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanomaL M Samuel, V J Harvey, P L Mitchell, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 9, 2001
Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humansS F Zhou, J W Paxton, M D Tingle, et al.
British Journal of Urology|October 1, 1992
Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumoursB M Colls, V J Harvey, L Skelton, et al.
British Journal of Cancer|January 1, 1992
Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronideD Hucks, P I Thompson, L McLoughlin, et al.
British Journal of Cancer|September 1, 1991
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomasP W Johnson, P I Thompson, M T Seymour, et al.
Australian and New Zealand Journal of Medicine|June 1, 1995
Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centresM B Jameson, B D Evans, D H Gray, et al.
BJU International|May 8, 1999
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New ZealandB M Colls, V J Harvey, L Skelton, et al.
British Journal of Cancer|June 12, 2003
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agentM B Jameson, P I Thompson, B C Baguley, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Chemotherapy and Pharmacology|October 6, 2006
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trialM B Jameson, B C Baguley, P Kestell, et al.
Cancer Chemotherapy and Pharmacology|June 15, 1999
Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamideM R McCrystal, B D Evans, V J Harvey, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanomaL M Samuel, V J Harvey, P L Mitchell, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 9, 2001
Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humansS F Zhou, J W Paxton, M D Tingle, et al.
British Journal of Urology|October 1, 1992
Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumoursB M Colls, V J Harvey, L Skelton, et al.
British Journal of Cancer|January 1, 1992
Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronideD Hucks, P I Thompson, L McLoughlin, et al.
British Journal of Cancer|September 1, 1991
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomasP W Johnson, P I Thompson, M T Seymour, et al.
Australian and New Zealand Journal of Medicine|June 1, 1995
Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centresM B Jameson, B D Evans, D H Gray, et al.
BJU International|May 8, 1999
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New ZealandB M Colls, V J Harvey, L Skelton, et al.
British Journal of Cancer|June 12, 2003
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agentM B Jameson, P I Thompson, B C Baguley, et al.
Pageof 2